Last reviewed · How we verify
NCT03008499
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
Completed
Phase 1, PHASE2
Last updated 12 September 2019
What this trial tests
Phase 1, PHASE2 trial testing High-activity natural killer in Metastatic Colorectal Cancer in 20 participants. Completed in 1 September 2019.
Timeline
1 December 2016
Primary endpoint
1 December 2017
1 December 2017
1 September 2019
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 December 2016 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 September 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- High-activity natural killer — full drug profile →
Conditions studied
- Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 30 to 60, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of colorectal cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of natural killer cell in gastrointestinal cancer: killer or helper.
Wang F, Lau JKC, Yu J. · · 2021 · cited 66× · PMID 33262461 · DOI 10.1038/s41388-020-01561-z -
Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.
Kather JN, Halama N. · · 2019 · cited 63× · PMID 30936499 · DOI 10.1038/s41416-019-0441-6 -
Immunotherapy in Gastrointestinal Cancers.
Procaccio L, Schirripa M, Fassan M, Vecchione L, et al · · 2017 · cited 54× · PMID 28758114 · DOI 10.1155/2017/4346576 -
Immunotherapy in colorectal cancer: for the select few or all?
Arora SP, Mahalingam D. · · 2018 · cited 48× · PMID 29564183 · DOI 10.21037/jgo.2017.06.10 -
Lipid nanoparticle-mediated RNA delivery for immune cell modulation.
Kim EH, Teerdhala SV, Padilla MS, Joseph RA, et al · · 2024 · cited 19× · PMID 39279550 · DOI 10.1002/eji.202451008 -
Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer.
Vafaei S, Roudi R, Madjd Z, Aref AR, et al · · 2020 · cited 19× · PMID 32655320 · DOI 10.1186/s12935-020-01389-3 -
Cell Therapy as Target Therapy against Colon Cancer Stem Cells.
Garza Treviño EN, Quiroz Reyes AG, Rojas Murillo JA, de la Garza Kalife DA, et al · · 2023 · cited 12× · PMID 37175871 · DOI 10.3390/ijms24098163 -
Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma.
Quiroz-Reyes AG, Islas JF, Delgado-Gonzalez P, Franco-Villarreal H, et al · · 2021 · cited 12× · PMID 33466892 · DOI 10.3390/pharmaceutics13010103
Verify or expand the search:
- PubMed search for NCT03008499
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of High-activity natural killer
Trials testing the same drug.
- NCT03008330 — High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer · Phase 1, PHASE2 · completed
- NCT03008304 — High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer · Phase 1, PHASE2 · completed
- NCT03007836 — High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer · Phase 1, PHASE2 · completed
- NCT03007823 — High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma · Phase 1, PHASE2 · completed
Other recruiting trials for Metastatic Colorectal Cancer
Currently open trials in the same condition.
- NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
- NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
- NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03008499 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 12 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03008499.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing